Assessing the Status of Cyclin E1 (CCNE1) From Gene to Protein Level in Ovarian and Endometrial Carcinomas: A Systematic Review
Open Access
- 11 October 2025
- journal article
- review article
- Published by Elsevier in Laboratory Investigation
- Vol. 105 (12) , 104249
Abstract
No abstract availableKeywords
Funding Information
- Cancéropôle Lyon Auvergne-Rhône-Alpes
- Hospices Civils de Lyon
- Institut National Du Cancer
This publication has 67 references indexed in Scilit:
- 617MO Safety and tolerability of INCB123667, a selective CDK2 inhibitor, in patients (pts) with advanced solid tumors: A phase I studyAnnals of Oncology, 2024
- Copy number signatures and CCNE1 amplification reveal the involvement of replication stress in high-grade endometrial tumors oncogenesisCellular Oncology, 2024
- CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium studyCancer, 2022
- Clinical implications of plasma circulating tumor DNA in gynecologic cancer patientsMolecular Oncology, 2020
- Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinomaThe Journal of Pathology: Clinical Research, 2020
- Histo‐genomic stratification reveals the frequent amplification/overexpression of CCNE1 and BRD4 genes in non‐BRCAness high grade ovarian carcinomaInternational Journal of Cancer, 2015
- Change in HER2 (ERBB2) gene status after taxane-based chemotherapy for breast cancer: polyploidization can lead to diagnostic pitfalls with potential impact for clinical managementCancer Genetics, 2013
- Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancerCancer, 2010
- Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinomaCancer, 2006
- Cyclin E overexpression and amplification in human tumoursThe Journal of Pathology, 2003